AstraZeneca partners with Regeneron to research obesity treatment

(Alliance News) - Anglo-Swedish pharmaceutical firm AstraZeneca PLC on Tuesday announced a ...

Alliance News 27 July, 2021 | 11:56AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Anglo-Swedish pharmaceutical firm AstraZeneca PLC on Tuesday announced a collaboration agreement with New York-based biotechnology firm Regeneron Pharmaceuticals Inc to research and develop small molecule compounds targeting GPR75 to treat obesity.

G Protein-Coupled Receptor 75 is a protein coding gene, which activates guanine-nucleotide binding proteins upon the binding of a ligand.

Recent research has found that individuals with at least one inactive copy of the GPR75 gene had a lower body mass index, and on average tends to weigh around 12 pounds less and face a 54% lower risk of obesity than those without the mutation.

Under the agreement, both companies will evenly split the research and development costs, as well as share equally in any future potential profits.

"We are pleased to announce this important collaboration with Regeneron to identify small molecule modulators against GPR75, a newly identified target with genetic validation in metabolic disorders. Obesity and insulin resistance remain key drivers in the development of type 2 diabetes and areas of significant unmet medical need," said Mene Pangalos, executive vice president of BioPharmaceuticals at AstraZeneca.

Shares in AstraZeneca were up 0.6% at 8,342.98 pence on Tuesday afternoon in London. Regeneron's shares closed 1.5% lower at USD577.78 on Monday in New York and were down 0.1% in pre-market trade on Tuesday.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 10,914.00 GBX -1.00
Regeneron Pharmaceuticals Inc 898.56 USD -0.68

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures